Novo Nordisk A/S (NYSE:NVO) Shares Down 2.9% – Here’s What Happened

Novo Nordisk A/S (NYSE:NVO)’s share price was down 2.9% during mid-day trading on Tuesday . The company traded as low as $35.85 and last traded at $36.68. Approximately 33,926,250 shares traded hands during trading, an increase of 26% from the average daily volume of 27,030,203 shares. The stock had previously closed at $37.76.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised its rating on NVO to Equal Weight, which reduces downside from prior negative sentiment and can steady investor expectations. Novo Nordisk A/S (NYSE:NVO) Raised to Equal Weight at Morgan Stanley
• Positive Sentiment: Market reaction: reports note NVO shares jumped as the FDA cracks down on telehealth GLP‑1 advertisers — investors view enforcement as reducing low‑cost competitors and protecting branded sales. Novo Nordisk (NVO) Stock Jumps 3% as FDA Cracks Down on Telehealth GLP-1 Advertisers
• Neutral Sentiment: Goldman Sachs reaffirmed a Neutral rating, signaling no near‑term catalyst from that house and supporting a wait‑and‑see stance among institutional holders. The Goldman Sachs Group Reaffirms “Neutral” Rating for Novo Nordisk A/S (NYSE:NVO)
• Neutral Sentiment: Coverage pieces debate valuation and whether current share weakness has overshot fundamentals — useful for longer‑term investors weighing buy/hold decisions but not an immediate catalyst. Novo Nordisk (NYSE:NVO) Valuation Debate Lingers As Market Awaits Catalyst Clarity
• Neutral Sentiment: Analytical article asks whether the share price is now pricing in excessive pessimism; highlights the stock could be attractive to value investors if regulatory/legal risks stabilize. Is Novo Nordisk (NYSE:NVO) Now Pricing In Too Much Pessimism After Share Price Slump
• Negative Sentiment: Regulatory risk: Reuters reports the FDA sent Novo a second warning telling the company to stop running a consumer Ozempic ad the agency deems false or misleading — this increases short‑term regulatory scrutiny and reputational risk. US FDA warns Novo for second time about misleading Ozempic advertising
• Negative Sentiment: Industry coverage: Becker’s reports the FDA issued a second warning over GLP‑1 advertising claims, reinforcing that promotional practices will be closely policed. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: Another report details the specific Ozempic “Only One” ad warning, underscoring the potential for additional corrective action or required ad changes. Novo Nordisk slammed with another FDA letter for ‘Only One Ozempic’ ad
• Negative Sentiment: Legal risk: Pomerantz launched an investor investigation into Novo Nordisk, which could signal potential shareholder litigation and increase legal costs or settlements if claims proceed. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO
• Negative Sentiment: Policy friction: the American Hospital Association urged HRSA to block Novo’s new claims‑data submission policy for 340B hospitals — a dispute that could affect hospital relations, reimbursement dynamics and public perception. AHA urges HRSA to stop Novo Nordisk’s new claims-data submission policy on 340B hospitals from going into effect
• Negative Sentiment: Market commentary (Seeking Alpha) reiterates the FDA warning story and highlights the reputational/regulatory overhang for GLP‑1 makers. Novo Nordisk gets another FDA warning over GLP-1 ad claims

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on NVO shares. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. CICC Research started coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. TD Cowen reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Finally, HSBC restated a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Five analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $53.93.

Novo Nordisk A/S Trading Up 1.4%

The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The business has a fifty day moving average of $51.96 and a 200-day moving average of $52.58. The stock has a market capitalization of $174.22 billion, a price-to-earnings ratio of 11.24 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s payout ratio is 23.63%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Martin Capital Partners LLC lifted its stake in Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after acquiring an additional 41,129 shares in the last quarter. Smith Chas P & Associates PA Cpas grew its stake in Novo Nordisk A/S by 105.3% during the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after acquiring an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC lifted its position in shares of Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after purchasing an additional 37,453 shares in the last quarter. Markel Group Inc. lifted its position in shares of Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after purchasing an additional 110,061 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth approximately $1,294,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.